Results

Merck & Co. Inc.

12/01/2021 | Press release | Distributed by Public on 12/01/2021 05:50

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and[...]